Anurag Singh, managing director of a consulting firm Primus Partners added that a combination of high-impact schemes have been put in place for pharma-sector recently, including PLIs for pharma, key starting materials (KSM), API, medical devices, scheme for promotion of bulk drug parks, medical device parks, etc. The net impact of the pandemic and supply chain disruptions in China have been favourable for the Indian pharma sector.